Shunji Haruta
Directeur Technique/Scientifique/R&D chez SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Profil
Shunji Haruta has worked as a Director at Satsuma Pharmaceuticals, Inc. since 2023 and as an Executive Officer & Research Manager at Shin Nippon Biomedical Laboratories, Ltd.
since 2001.
Postes actifs de Shunji Haruta
| Sociétés | Poste | Début |
|---|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Directeur Technique/Scientifique/R&D | 01/01/2011 |
| SATSUMA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 08/06/2023 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. | Commercial Services |
| Entreprise privées | 1 |
|---|---|
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
